We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Microneedle Skin Patch Detects Melanoma Without Biopsy or Blood Draw

By LabMedica International staff writers
Posted on 28 Jul 2025

Melanoma, the most aggressive form of skin cancer, currently requires patients, especially those with fair skin and moles, to undergo regular doctor visits and biopsies every six months to determine if growths are malignant or benign. More...

This process can be invasive, costly, and time-consuming. Traditional diagnostic methods often involve blood draws or surgical biopsies, making them inaccessible for routine, rapid screening. Detecting melanoma early is crucial to improving outcomes, but limitations in current testing options delay diagnosis and increase patient anxiety. Now, researchers have developed a skin patch and test strip that allow for non-invasive, rapid detection of melanoma without the need for a biopsy or blood sample.

ExoPatch, developed by researchers at the University of Michigan (Ann Arbor, MI, USA), is a silicone patch embedded with star-shaped microneedles that are just 0.6 mm long. These microneedles are coated with a gel containing Annexin V protein that attracts and captures exosomes, tiny vesicles released by cells from interstitial fluid in the epidermis. Once applied to the skin, the microneedles painlessly penetrate only the topmost layer without drawing blood. After 15 minutes, the patch is removed and placed in acid, dissolving the gel and releasing the exosomes into a solution. A test strip, similar to an at-home COVID-19 test, is then dipped into the solution: two lines indicate the presence of melanoma exosomes, while one line indicates a negative result.

The ExoPatch was first validated on pig skin samples due to their similarity to human skin, with microscopy confirming microneedle penetration of 350 to 600 nanometers well within the epidermis. The system was then tested on tissue samples from mice, half of which had been injected with human melanoma tumor fragments. The patch successfully adhered to exosomes in the 30 to 150 nanometer range and was able to distinguish between melanoma and healthy tissue with a 3.5-fold darker test line for melanoma samples. The findings, published in Biosensors and Bioelectronics, showed that the patch isolated 11.5 times more exosomal protein from melanoma tissues, indicating high specificity. Future plans include a pilot study in humans followed by clinical trials. The gel coating of the ExoPatch could also be modified to detect exosomes from other solid tumors such as lung, breast, colon, prostate, and brain cancers.

“This is the first patch designed to capture disease-specific exosomes from fluid under the skin. The potential applications are huge,” said Sunitha Nagrath, co-corresponding author of the study.

Related Links:
University of Michigan


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The AidaBREAST assay integrates multimodal data to provide patient-specific 10-year recurrence risk and individualized predictions of radiation therapy benefit (photo courtesy of PreludeDx)

Validated Test Predicts Recurrence Risk and Radiation Benefit in Early-Stage Breast Cancer

For women with early-stage invasive breast cancer who undergo breast-conserving surgery, clinicians must assess both the risk of locoregional recurrence and the potential benefit of adjuvant radiation therapy.... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Industry

view channel
Image: Natera\'s MCED assay analyzes cell-free DNA in blood to screen for multiple cancers (Image Credit: Adobe Stock)

Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation

Natera Inc.’s (Austin, TX, USA) multi-cancer early detection (MCED) assay has received Breakthrough Device designation (BDD) from the U.S. Food and Drug Administration (FDA). The assay analyzes cell-free... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.